Takara Bio Signs Exclusive License Agreement with Otsuka for the Investigational Cancer Treatment HF10, an Oncolytic Virus
Takara Bio Signs Exclusive License Agreement with Otsuka for the Investigational Cancer Treatment HF10, an Oncolytic Virus Kusatsu/Shiga, Japan — December 15, 2016 — Takara Bio Inc. (Takara) announced today that it has entered into an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for co-development and commercialization in Japan of the oncolytic virus... Read more